舒降之对原发高脂血症并急性冠脉综合征早期疗效观察  

Earlier clinical observation of zocor (20mg) efficacy on primary hyperlipaemia and acute coronary syndrome

作　　者：白杨 程火星 

机构地区：[1]广州市东升医院,510120 [2]广州市广钢医院

出　　处：《中国实用医药》2008年第31期39-40,共2页China Practical Medicine

摘　　要：目的观察在原发高脂血症合并急性冠脉综合征早期应用辛伐他汀对降低血脂的疗效及缺血事件发生的影响。方法将48例原发高脂血症合并急性冠脉综合征(ACS)患者随机分为试验组A24例和对照组B 24例。试验组A在两组治疗常规相同基础上,每晚顿服辛伐他汀(舒降之)20 mg,疗程6周,观察用药前后血脂变化及缺血事件的发生情况。结果对照组治疗前后血脂无明显变化,试验组用药前后血脂明显下降(P<0.05),缺血事件发生率明显下降(P<0.05)。结论原发高脂血症合并急性冠脉综合征,早期每晚应用舒降之20mg降脂疗效确切及明显降低缺血事件的发生。Objective Observe the blood lipid-reducing efficacy of the simvastatin on earlier stage of primary hyperlipaemia and acute coronary syndrome and the affection of ischemia event. Methods Randomly divide 48 cases of the patients suffered from primary hyperlipemia and acute coronary syndrome （ACS） into a treatment group A24 and a control group B24. On the basis of the same normal treatment for both groups, the treatment group A takes 20mg simvastatin （Zocor） every evening for a treatment course of 6 weeks. Then, observe the change of blood lipid before and after the administration, as well as the occurrence of ischemia events. Results The blood lipid of the control group has no change before and after the treatment, while that of the treatment group reduces obviously （P 〈 0. 05）. Conclusion The patients suffered from primary hyperlipemia and acute coronary syndrome should take 20rag Zocor every evening at the earlier stage, which has definite lipid-reducing efficacy and can obviously decrease the occurrence of ischemia event.

关 键 词：高脂血症 急生冠脉综合征 缺血事件 舒降之 

分 类 号：R589.2[医药卫生—内分泌] R541.4[医药卫生—内科学]